Loading institutional data...
Loading institutional data...
No institutional (13F) filings cover this company, so the Overview and 13F tabs are thin. Everything drawn from its SEC filings is here.
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $100.0M buybacks = $100.0M returned on $60.2M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A balanced mix of reinvestment and shareholder returns.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 5%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
How a revenue dollar becomes profit — FY2024
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it. This year they exceeded net income, so the ribbons are capped at earnings and understate what was actually returned.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $277.2M 100.0% | $232.3M 100.0% | $722.7M 100.0% | $439.4M 100.0% | $46.6M 100.0% | $35.2M 100.0% | $8.2M 100.0% | $327K 100.0% | $11.0M 100.0% | $4.0M 100.0% |
| Research & Development | $61.5M 22.2% | $54.9M 23.6% | $46.6M 6.4% | $32.2M 7.3% | $28.6M 61.5% | $62.3M 177.0% | $75.0M 914.3% | $65.0M 19874.0% | $84.5M 765.1% | $86.9M 2146.7% |
| Selling, General & Admin | $170.4M 61.5% | $152.9M 65.8% | $131.4M 18.2% | $100.2M 22.8% | $79.3M 170.3% | $75.0M 212.9% | $64.8M 790.1% | $27.4M 8369.1% | $37.3M 337.4% | $22.2M 547.7% |
| Total Operating Expenses | $281.4M 101.5% | $269.3M 115.9% | $439.2M 60.8% | $305.0M 69.4% | $114.9M 246.9% | $170.1M 482.9% | $161.5M 1970.2% | $96.3M 29459.3% | $121.8M 1102.5% | $109.1M 2694.4% |
| Operating Income | -$4.1M -1.5% | -$37.0M -15.9% | $283.5M 39.2% | $134.5M 30.6% | -$68.4M -146.9% | -$134.8M -382.9% | -$153.3M -1870.2% | -$96.0M -29359.3% | -$110.7M -1002.5% | -$105.1M -2594.4% |
| Interest Expense | $6.8M 2.5% | $6.8M 2.9% | $6.7M 0.9% | $11.2M 2.5% | $19.1M 40.9% | $17.0M 48.2% | $9.3M 113.9% | — | — | $572K 14.1% |
| Interest & Investment Income | $36.5M 13.2% | $32.0M 13.8% | $7.9M 1.1% | $140K 0.0% | $1.3M 2.7% | $3.4M 9.6% | $3.8M 46.7% | $1.3M 408.9% | $755K 6.8% | $205K 5.1% |
| Other Income (Expense), net | $293K 0.1% | -$152K -0.1% | $111K 0.0% | $922K 0.2% | -$897K -1.9% | $731K 2.1% | -$70K -0.9% | -$486K -148.6% | -$2.5M -22.6% | $317K 7.8% |
| Pretax Income | $30.9M 11.1% | -$4.4M -1.9% | $294.3M 40.7% | $77.5M 17.6% | -$75.2M -161.6% | -$152.6M -433.3% | -$158.9M -1938.3% | -$95.2M -29099.1% | -$112.4M -1018.2% | -$106.8M -2636.9% |
| Income Tax Expense | $3.5M 1.3% | $2.0M 0.9% | $1.1M 0.2% | $808K 0.2% | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% |
| Net Income | $27.3M 9.9% | -$6.4M -2.8% | $293.2M 40.6% | $76.7M 17.5% | -$75.2M -161.6% | -$152.6M -433.3% | -$158.9M -1938.3% | -$95.2M -29099.1% | -$112.4M -1018.2% | -$106.8M -2636.9% |
| Per Share | ||||||||||
| EPS (Basic) | $0.21 | -$0.05 | $2.32 | $0.62 | -$0.75 | -$2.16 | -$2.55 | — | — | — |
| EPS (Diluted) | $0.20 | -$0.05 | $1.97 | $0.57 | -$0.78 | -$2.16 | -$2.55 | — | — | — |
| Weighted Avg Shares (Basic) | 130.0M | 128.7M | 126.4M | 116.3M | 100.8M | 72.0M | 62.4M | — | — | — |
| Weighted Avg Shares (Diluted) | 133.3M | 128.7M | 150.8M | 133.0M | 101.5M | 72.0M | 62.4M | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 85 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-06-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $1.05T | 51.4× | — | 16.1× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,500 |
| JNJ | $630.0B | 23.7× | 20.0× | 6.7× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | 0.9× | 4,554 |
| ABBV | $488.6B | 117.2× | 34.8× | 8.0× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 3.9× | 4,062 |
| MRK | $359.2B | 20.0× | — | 5.5× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,683 |
| ABT | $172.3B | 26.8× | 18.6× | 3.9× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 0.5× | 2,876 |
| PFE | $161.2B | 20.8× | — | 2.6× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,748 |
| VRTX | $129.3B | 33.3× | 28.3× | 10.8× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | -1.2× | 1,689 |
| BMY | $120.8B | 17.1× | — | 2.5× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,451 |
| REGN | $76.9B | 18.0× | 18.4× | 5.4× | 1.0% | — | 31.4% | 14.4% | 13.6% | -0.3× | 1,291 |
| TEVA | $47.9B | 34.0× | 17.9× | 2.8× | 4.3% | 51.8% | 8.2% | 17.8% | 14.5% | -0.7× | 658 |
| ONC | $40.3B | — | 62.4× | 7.5× | 40.2% | 87.5% | 5.4% | 6.6% | 5.4% | -6.1× | 269 |
| ALNY | $31.1B | 99.9× | 53.0× | 8.4× | 65.2% | 81.8% | 8.4% | 39.8% | 39.8% | -3.0× | 760 |
| ZTS | $30.9B | 12.4× | 9.8× | 3.3× | 2.3% | 71.8% | 28.2% | 78.3% | 21.5% | 1.7× | 1,363 |
| RPRX | $25.3B | 32.0× | 21.5× | 10.7× | 5.1% | — | 32.4% | 7.9% | 4.1% | 5.3× | 621 |
| UTHR | $23.6B | 19.7× | 13.9× | 7.4× | 10.6% | 87.9% | 41.9% | 18.8% | 18.8% | -1.0× | 843 |
| INSM | $22.0B | — | — | 36.2× | 66.7% | 79.7% | -211% | -173% | -99.8% | — | 644 |
| CORT | $13.1B | 147.8× | — | 17.2× | 12.8% | 98.3% | 13.1% | 15.4% | 15.4% | -2.6× | 416 |
| ELAN | $11.4B | — | — | 2.4× | 6.2% | 55.0% | -4.9% | -3.5% | -2.2% | — | 495 |
| BMRN | $10.6B | 30.4× | 20.2× | 3.3× | 12.9% | 77.7% | 10.8% | 5.7% | 5.2% | -1.5× | 545 |
| TGTX | $8.5B | 20.0× | 70.0× | 13.8× | 87.3% | 83.7% | 72.6% | 69.0% | 50.0% | 1.4× | 419 |
| IONS | $7.5B | — | — | 8.0× | 33.8% | 98.3% | -40.4% | -78.0% | -17.0% | — | 498 |
| AMRX | $6.9B | 90.5× | 20.4× | 2.3× | 8.0% | 36.9% | 2.4% | -102% | 2.9% | 5.1× | 298 |
| ALKS | $6.8B | 28.4× | 22.9× | 4.6× | -5.2% | 86.7% | 16.4% | 13.3% | 13.3% | -1.4× | 410 |
| RYTM | $6.3B | — | — | 32.9× | 45.8% | 89.7% | -104% | -141% | -79.5% | — | 296 |
| KNSA | $6.2B | 106.4× | 78.3× | 9.2× | 60.1% | 88.5% | 8.7% | 10.4% | 10.4% | -2.1× | — |
| DVAX | — | — | — | — | 19.4% | — | 9.9% | 4.6% | 4.6% | — | — |
Peers = companies sharing DVAX's sector (Pharmaceutical Preparations) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
No current price collected.
Where each multiple sits in its own 13-yr range
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 13-yr history.
Is the profit real, and how strong is the balance sheet?
FY2024 · every deduction from revenue to net income
DuPont — the three levers
ROE 5% against ROIC 5% — 0% of the return on equity comes from leverage and buybacks rather than from the operating business.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|
| R&D | 19874.0 | 914.3 | 177.0 | 61.5 | 7.3 | 6.4 | 23.6 | 22.2 |
| SG&A | 8369.1 | 790.1 | 212.9 | 170.3 | 22.8 | 18.2 | 65.8 | 61.5 |
| Operating Income | -29359.3 | -1870.2 | -382.9 | -146.9 | 30.6 | 39.2 | -15.9 | -1.5 |
| Income Tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.9 | 1.3 |
| Net Income | -29099.1 | -1938.3 | -433.3 | -161.6 | 17.5 | 40.6 | -2.8 | 9.9 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on DVAX: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
Cost of capital cannot be computed, so the spread is unknown.
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2015 | not reported | -2594.4% | -2636.9% |
| FY2016 | not reported | -1002.5% | -1018.2% |
| FY2017 | not reported | -29359.3% | -29099.1% |
| FY2018 | not reported | -1870.2% | -1938.3% |
| FY2019 | not reported | -382.9% | -433.3% |
| FY2020 | not reported | -146.9% | -161.6% |
| FY2021 | not reported | 30.6% | 17.5% |
| FY2022 | not reported | 39.2% | 40.6% |
| FY2023 | not reported | -15.9% | -2.8% |
| FY2024 | not reported | -1.5% | 9.9% |
Return on equity (5%) and return on invested capital (5%) are within a couple of points in FY2024, so the headline return is the operating return — there is no meaningful leverage effect to strip out.
No material counter-signal in the checked set: ROIC vs WACC spread, 5-year spread history, gross margin trend, operating margin trend, net margin against 3 years ago, revenue growth, ROIC ex-goodwill gap.
Missing from our data, so excluded from this answer: beta, market_cap.
Cash conversion is 2.21x but SBC is 18.98% of revenue.
Cash conversion is strong at 2.21x, but SBC is 18.98% of revenue — the cash flow looks clean partly because paying people in stock never passes through it.
Debt is present but there is no positive EBITDA or no reported interest expense, so coverage cannot be measured.
Balance sheet at 2024-12-31. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
No material counter-signal in the checked set: net debt / EBITDA, interest coverage, stressed coverage, maturity schedule vs cash and one year of FCF, liquidity ratios.
Missing from our data, so excluded from this answer: ebitda.
No current price or share count, so the market's assumption cannot be solved for.
No material counter-signal in the checked set: reverse-DCF implied growth, historical FCF CAGR, per-year FCF growth distribution, reporting-basis breaks, discount rate used, free-cash-flow basis (stock comp charged?).
Missing from our data, so excluded from this answer: market_cap.
| Step | Amount | Running total |
|---|---|---|
| Net income | $27M | $27M |
| Share-based comp | $53M | $80M |
| Other non-cash & working capital | −$13M | $67M |
| Operating cash flow | $67M | $67M |
| Capex | −$6M | $60M |
| Free cash flow | $60M | $60M |
| FCF after SBC | $8M | $8M |
| Fiscal year | Revenue growth | Receivables growth | Gap |
|---|---|---|---|
| FY2019 | 329.6% | not reported | not reported |
| FY2020 | 32.2% | not reported | not reported |
| FY2021 | 844.0% | not reported | not reported |
| FY2022 | 64.5% | not reported | not reported |
| FY2023 | -67.9% | not reported | not reported |
| FY2024 | 19.4% | not reported | not reported |
| Fiscal year | Accruals / assets |
|---|---|
| FY2018 | -13.1 percent |
| FY2019 | -11.2 percent |
| FY2020 | 4.8 percent |
| FY2021 | -24.9 percent |
| FY2022 | 23.4 percent |
| FY2023 | -10.7 percent |
| FY2024 | -4.0 percent |
SBC is added back inside operating cash flow, so reported free cash flow treats shares issued to employees as free. Percent of revenue says how expensive the payroll is; percent of operating cash flow says how much of the cash exists only because the charge was added back. The buyback offset is buybacks over SBC — below 1.0 the repurchase does not cover the shares issued.
Figures are the latest fiscal year (FY2024) from the company's own filings, not a trailing-twelve-month window — Q2 reads fiscal years throughout so the cash-conversion ratios and these share one basis. A blank is a line the filer did not report; it is never read as zero.